Sp2 Inhibitors
Sp2 inhibitors refer to a class of chemical compounds characterized by their ability to interfere with the biological activity of molecules containing sp2 hybridized carbon atoms. In organic chemistry, sp2 hybridization occurs when a carbon atom forms three sigma bonds with three other atoms and possesses one unhybridized p orbital. This unhybridized p orbital allows for the formation of pi (π) bonds, which are crucial for the stability and reactivity of various organic molecules. Sp2 inhibitors, therefore, target compounds or biomolecules that rely on π bonds for their function.
These inhibitors often act by disrupting the conjugated pi system in sp2-hybridized compounds, leading to alterations in the electronic structure and, subsequently, the reactivity of these molecules. They can function as competitive inhibitors, covalently modifying their target molecules, or interfering with the delocalized electron density within the π system. Sp2 inhibitors find applications in various fields of chemistry, including medicinal chemistry and drug discovery, as they can target specific biological macromolecules like enzymes, receptors, or DNA, affecting their activity.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
Tamoxifen competes with estrogen for binding to estrogen receptors, inhibiting their activation and preventing estrogen-driven tumor growth in breast cancer. It acts as a selective estrogen receptor modulator (SERM). | ||||||
Anastrozole | 120511-73-1 | sc-217647 | 10 mg | $92.00 | 1 | |
Anastrozole inhibits aromatase, an enzyme responsible for converting androgens into estrogen. By reducing estrogen levels, it is used for hormone receptor-positive breast cancer. | ||||||
Letrozole | 112809-51-5 | sc-204791 sc-204791A | 25 mg 50 mg | $87.00 $147.00 | 5 | |
Letrozole, like anastrozole, inhibits aromatase, decreasing estrogen production and consequently slowing the growth of hormone receptor-positive breast tumors. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib targets the epidermal growth factor receptor (EGFR), blocking downstream signaling pathways involved in cell proliferation and survival in lung cancer. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib inhibits the EGFR tyrosine kinase, reducing cancer cell growth and division, primarily in lung and pancreatic cancer. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib selectively inhibits tyrosine kinases such as BCR-ABL, KIT, and PDGF-R, which are often mutated and overactive in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib targets multiple kinases involved in tumor growth, angiogenesis, and metastasis, making it effective against renal cell carcinoma and hepatocellular carcinoma. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib inhibits multiple receptor tyrosine kinases, including VEGFR, PDGFR, and KIT, blocking tumor vascularization and growth in renal cell carcinoma and gastrointestinal stromal tumors. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Vemurafenib specifically targets BRAF V600E-mutated protein, inhibiting the MAPK signaling pathway in melanoma cells with this mutation. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib inhibits MEK1 and MEK2, key components of the MAPK pathway, disrupting cell proliferation and survival signals in BRAF V600E-mutated melanoma. | ||||||